LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Medtronic PLC

Chiusa

SettoreSettore sanitario

83.04 0.84

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

82.94

Massimo

83.26

Metriche Chiave

By Trading Economics

Entrata

16M

1.3B

Vendite

-111M

8.3B

P/E

Media del settore

22.349

53.54

EPS

1.62

Rendimento da dividendi

3.52

Margine di Profitto

15.605

Dipendenti

95,000

EBITDA

-42M

2.4B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+15.85% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.52%

2.44%

Utili prossimi

19 ago 2025

Prossima data del Dividendo

11 lug 2025

Prossima data del' Ex Dividendo

27 giu 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-17B

103B

Apertura precedente

82.2

Chiusura precedente

83.04

Notizie sul Sentiment di mercato

By Acuity

34%

66%

91 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Medtronic PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2025, 11:38 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18 feb 2025, 12:24 UTC

Utili

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21 mag 2025, 17:23 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21 mag 2025, 11:39 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21 mag 2025, 10:52 UTC

Utili

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21 mag 2025, 10:51 UTC

Utili

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21 mag 2025, 10:50 UTC

Utili

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21 mag 2025, 10:49 UTC

Utili

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21 mag 2025, 10:49 UTC

Utili

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21 mag 2025, 10:48 UTC

Utili

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21 mag 2025, 10:48 UTC

Utili

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21 mag 2025, 10:47 UTC

Utili

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21 mag 2025, 10:45 UTC

Acquisizioni, Fusioni, Takeovers

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Net $1.06B >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Diabetes Rev $728M >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Adj EPS $1.62 >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q EPS 82c >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21 mag 2025, 10:45 UTC

Utili

Medtronic 4Q Sales $8.93B >MDT

21 mag 2025, 09:00 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21 mag 2025, 09:00 UTC

Acquisizioni, Fusioni, Takeovers

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21 mag 2025, 09:00 UTC

Acquisizioni, Fusioni, Takeovers

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21 mag 2025, 09:00 UTC

Acquisizioni, Fusioni, Takeovers

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27 feb 2025, 10:30 UTC

Notizie principali

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 feb 2025, 11:47 UTC

Utili

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 feb 2025, 11:46 UTC

Utili

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Confronto tra pari

Modifica del prezzo

Medtronic PLC Previsione

Obiettivo di Prezzo

By TipRanks

15.85% in crescita

Previsioni per 12 mesi

Media 96.13 USD  15.85%

Alto 109 USD

Basso 87 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Medtronic PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

20 ratings

11

Acquista

9

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

83.26 / 84.875Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

91 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.